GBIO Generation Bio Co.

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

$27.16  -1.48 (-5.17%)
As of 04/09/2021 15:59:54 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/12/2020
Outstanding shares:  56,427,399
Average volume:  693,969
Market cap:   $1,534,825,253
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    37148K100
ISIN:        US37148K1007
Sedol:      BMC2Z79
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   5.73
PS ratio:   0.00
Return on equity:   -30.04%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy